Clinical trial
A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).
NCT00499590 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).
- Lead sponsor
- OPKO Health, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 31, 2007
- Completion date
- May 31, 2009
- Enrollment
- 338 (actual)
- Sites
- 60
Conditions
As the registry lists them; a condition with its own page is linked.